90 related articles for article (PubMed ID: 30209731)
1. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
2. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis.
Genuino AJ; Chaikledkaew U; The DO; Reungwetwattana T; Thakkinstian A
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):815-824. PubMed ID: 31287333
[No Abstract] [Full Text] [Related]
4. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis.
Stewart P; Blanchette P; Shah PS; Ye XY; Boldt RG; Fernandes R; Vandenberg T; Raphael J
Breast; 2020 Dec; 54():203-210. PubMed ID: 33130486
[TBL] [Abstract][Full Text] [Related]
5. 6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis.
Wang BC; Xiao BY; Fan JQ; Lin GH; Wang C; Liu Q; Zhao YX
Medicine (Baltimore); 2021 Mar; 100(10):e24995. PubMed ID: 33725875
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
Hiller L; Dunn JA; Loi S; Vallier AL; Howe DL; Cameron DA; Miles D; Wardley AM; Earl HM
BMC Cancer; 2018 Apr; 18(1):391. PubMed ID: 29621991
[TBL] [Abstract][Full Text] [Related]
7. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
Gallagher CM; More K; Kamath T; Masaquel A; Guerin A; Ionescu-Ittu R; Gauthier-Loiselle M; Nitulescu R; Sicignano N; Butts E; Wu EQ; Barnett B
Breast Cancer Res Treat; 2016 May; 157(1):145-56. PubMed ID: 27107569
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: A pilot study.
Wang J; Xu R; Yuan H; Zhang Y; Cheng S
Medicine (Baltimore); 2019 Jun; 98(26):e15872. PubMed ID: 31261495
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis.
Werner MS; Aras S; Morgan AR; Roamer J; Param NJ; Olagbegi K; Lamontagne RJ; Greig JA; Wilson JM
Cancer Gene Ther; 2024 May; 31(5):766-777. PubMed ID: 38480976
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; Lobbezoo DJ; de Boer M; Dercksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; de Vries B; Joore MA; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2015 Aug; 20(8):856-63. PubMed ID: 26099745
[TBL] [Abstract][Full Text] [Related]
11. Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer.
Kolarova I; Dusek L; Ryska A; Odrazka K; Dolezel M; Vanasek J; Melichar B; Petera J; Buchler T; Vosmik M; Petrakova K; Terarova P; Vilasova Z; Jarkovsky J
In Vivo; 2020; 34(6):3441-3449. PubMed ID: 33144452
[TBL] [Abstract][Full Text] [Related]
12. HER2 positive bilateral metachronous primary breast carcinoma: A case report.
Yao J; Liu J; Li Y; Li Y; Wu Q; Yang Y
Cancer Biol Ther; 2018 May; 19(5):349-354. PubMed ID: 29333901
[TBL] [Abstract][Full Text] [Related]
13. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
14. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
15. Deep learning-assisted monitoring of trastuzumab efficacy in HER2-Overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers.
Kim J; Son HY; Lee S; Rho HW; Kim R; Jeong H; Park C; Mun B; Moon Y; Jeong E; Lim EK; Haam S
Biosens Bioelectron; 2024 Aug; 258():116347. PubMed ID: 38723332
[TBL] [Abstract][Full Text] [Related]
16. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
[TBL] [Abstract][Full Text] [Related]
17. Long-term complete response to intrathecal trastuzumab in a patient with leptomeningeal carcinomatosis due to her2- overexpressing breast cancer: Case report.
García FJV; Carrión NP; de la Cruz-Merino L
Medicine (Baltimore); 2020 Jan; 99(1):e18298. PubMed ID: 31895768
[TBL] [Abstract][Full Text] [Related]
18. A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
Brezden-Masley C; Fathers KE; Coombes ME; Pourmirza B; Xue C; Jerzak KJ
Breast Cancer Res Treat; 2021 Feb; 185(3):807-815. PubMed ID: 33090268
[TBL] [Abstract][Full Text] [Related]
19. Validation of the RSClin risk calculator in the National Cancer Data Base.
Vannier AGL; Dhungana A; Zhao F; Chen N; Shubeck S; Hahn OM; Nanda R; Jaskowiak NT; Fleming GF; Olopade OI; Pearson AT; Huo D; Howard FM
Cancer; 2024 Apr; 130(8):1210-1220. PubMed ID: 38146744
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment strategy evolution and risk stratification for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in China.
Fan Y; Ji D; Jiang M; Tan Y; Yang Y; Li T; Ma X; Xu B
Oncologist; 2024 May; ():. PubMed ID: 38780143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
